glenmark

FDA approves Glenmark’s generic version of Novartis’ Exjade tablets for chronic iron overload

pharmafile | January 7, 2020 | News story | Manufacturing and Production, Research and Development |  Glenmark, exjade, generic, pharma 

Indian pharma firm Glenmark has announced it has secured approval from the FDA for its oral deferasirox tablets in the treatment of high iron levels in the body as a result of multiple blood infusions.

The therapy is a generic version of Novartis’ Exjade iron chelator tablets used in the treatment of chronic iron overload, a condition which can eventually lead to organ damage and potentially serious conditions such as heart disease and diabetes. In the 12 months ending in November last year, the therapy generated $106.4 million in sales for Novartis.

The approval covers the Mumbai-based firm’s 125mg, 250mg and 500mg tablet formulations. Glenmark’s share price elevated by around 1.37% with the reveal of the news.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content